Latest Breaking News On - Global regulatory affairs quality - Page 1 : comparemela.com

Next-generation instrument screens for hemoglobin disorders

Sebia’s CAPILLARYS 3 DBS instrument is an automated, multitasking capillary electrophoresis instrument

United statesArnaud collinSebia group viceLaboratory information systemGlobal regulatory affairs qualityDrug administrationProduct newsNext generation instrument screens for hemoglobin disorders in newborns sebia uk limited hemoglobinopathiesApillarys 3 dbs

Sebia Receives U S FDA Clearance for the CAPILLARYS 3 DBS devices

Sebia Receives U S FDA Clearance for the CAPILLARYS 3 DBS devices
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalArnaud collinDrug administrationSebia group viceGlobal regulatory affairs qualityZeus scientificTethys invest

Sebia Receives U S FDA Clearance for the FLC Kappa & Lambda Assays

Sebia Receives U S FDA Clearance for the FLC Kappa & Lambda Assays
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

France generalArnaud collinDrug administrationGlobal regulatory affairs qualityInternational myeloma working groupSebia group viceMultiple myelomaImmunoglobulin light chainZeus scientificTethys investMyeloma working group

Sebia Receives U S FDA Clearance for the FLC Kappa & Lambda Assays

Sebia, a global specialty diagnostic company providing innovative solutions for screening and diagnostics in oncology, metabolic diseases, genetic disorders and autoimmune diseases, today announced that it has received 510(k) clearance from the U.S..

France generalArnaud collinDrug administrationSebia group viceGlobal regulatory affairs qualityProduct serviceInternational myeloma working groupMultiple myelomaImmunoglobulin light chainZeus scientificTethys investMyeloma working group